AU4767400A
(en)
|
1999-04-30 |
2000-12-28 |
Cyclops Genome Sciences Limited |
Isolation of nucleic acid
|
US7011833B1
(en)
|
1999-05-06 |
2006-03-14 |
Genetics Institute, Inc. |
Enhancing immune responses with B7-1 or B7-2 in the absence of a crosslinking agent
|
WO2000067788A2
(en)
*
|
1999-05-06 |
2000-11-16 |
Genetics Institute, Inc. |
Use of soluble costimulatory molecules to enhance immune responses
|
HUP0300369A2
(hu)
|
2000-04-11 |
2003-06-28 |
Genentech, Inc. |
Többértékű antitestek és alkalmazásuk
|
KR100419555B1
(ko)
*
|
2000-05-29 |
2004-02-19 |
주식회사유한양행 |
비형간염바이러스의 에스-표면항원을 인식하는단일클론항체의 가변영역 및 이를 코딩하는 유전자
|
CA2410551A1
(en)
*
|
2000-06-30 |
2002-01-10 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) |
Heterodimeric fusion proteins
|
CN1461344A
(zh)
*
|
2000-07-25 |
2003-12-10 |
免疫医疗公司 |
多价靶结合蛋白
|
ATE547525T1
(de)
*
|
2000-08-08 |
2012-03-15 |
Zymogenetics Inc |
Lösliche zcyctor 11 cytokinrezeptoren
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
JP4619580B2
(ja)
*
|
2001-07-30 |
2011-01-26 |
デンカ生研株式会社 |
抗体捕捉法による抗体の免疫学的測定方法
|
US7084257B2
(en)
|
2001-10-05 |
2006-08-01 |
Amgen Inc. |
Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
|
US20050069549A1
(en)
|
2002-01-14 |
2005-03-31 |
William Herman |
Targeted ligands
|
AT500648B1
(de)
|
2002-08-12 |
2010-03-15 |
Igeneon Krebs Immuntherapie |
Set zur behandlung von krebspatienten
|
DE602004031390D1
(de)
|
2003-05-06 |
2011-03-24 |
Syntonix Pharmaceuticals Inc |
Gerinnungsfaktor VII-Fc chimäre Proteine zur Behandlung von hämostatischen Krankheiten
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
EP1629013B1
(de)
*
|
2003-05-31 |
2018-01-24 |
Amgen Research (Munich) GmbH |
Pharmazeutische zusammensetzungen, die einen für epcam spezifischen bispezifischen antikörper enthalten
|
ATE474856T1
(de)
|
2004-10-22 |
2010-08-15 |
Zymogenetics Inc |
Anti-il-22ra-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen
|
DK1866339T3
(da)
|
2005-03-25 |
2013-09-02 |
Gitr Inc |
GTR-bindende molekyler og anvendelser heraf
|
WO2006138739A2
(en)
|
2005-06-17 |
2006-12-28 |
Tolerx, Inc. |
Ilt3 binding molecules and uses therefor
|
CN101282745B
(zh)
|
2005-07-25 |
2015-04-29 |
新兴产品开发西雅图有限公司 |
用cd37-特异性和cd20-特异性结合分子减少b-细胞
|
MX2008015524A
(es)
*
|
2006-06-12 |
2009-01-13 |
Trubion Pharmaceuticals Inc |
Proteinas de union multivalentes monocatenarias con funcion efectora.
|
JP5597793B2
(ja)
|
2006-06-19 |
2014-10-01 |
メルク・シャープ・アンド・ドーム・コーポレーション |
Ilt3結合分子およびその使用
|
AT504942B1
(de)
|
2007-03-07 |
2009-08-15 |
Biomedica Medizinprodukte Gmbh |
Verfahren zur bestimmung von probnp
|
CA2693677C
(en)
|
2007-07-12 |
2018-02-13 |
Tolerx, Inc. |
Combination therapies employing gitr binding molecules
|
SI2132228T1
(sl)
|
2008-04-11 |
2011-10-28 |
Emergent Product Dev Seatle |
CD37 imunoterapevtik in kombinacija z njegovim bifunkcionalnim kemoterapevtikom
|
MX338825B
(es)
|
2008-10-02 |
2016-05-03 |
Emergent Product Dev Seattle |
Proteinas de enlace a objetivos multiples de antagonistas de cd86.
|
US8809507B2
(en)
*
|
2008-12-05 |
2014-08-19 |
Vuong Trieu |
SPARC binding ScFvs
|
US8796420B2
(en)
|
2009-12-31 |
2014-08-05 |
Avidbiotics Corp. |
Non-natural MIC proteins
|
US8658765B2
(en)
|
2009-12-31 |
2014-02-25 |
Avidbiotics Corp. |
Non-natural MIC proteins
|
CA2817015A1
(en)
|
2010-11-09 |
2012-05-18 |
Altimab Therapeutics, Inc. |
Protein complexes for antigen binding and methods of use
|
KR102244173B1
(ko)
|
2010-11-30 |
2021-04-26 |
추가이 세이야쿠 가부시키가이샤 |
세포상해 유도 치료제
|
JP6130307B2
(ja)
|
2011-03-17 |
2017-05-17 |
ザ ユニバーシティ オブ バーミンガム |
再指向性免疫療法
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
DE102012020496A1
(de)
|
2012-10-18 |
2014-04-24 |
Charité - Universitätsmedizin Berlin |
Biomarker zur Diagnostik und Behandlung von Neurofibromatose Typ 1
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
BR112016018408A2
(pt)
|
2014-03-14 |
2017-12-26 |
Immutep Sas |
moléculas de anticorpo à lag-3 e usos das mesmas
|
ES2939760T3
(es)
|
2014-03-15 |
2023-04-26 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico para antígenos
|
EP3130606B1
(de)
|
2014-04-07 |
2021-10-13 |
Chugai Seiyaku Kabushiki Kaisha |
Immunaktivierende bispezifische antikörper
|
US11505605B2
(en)
*
|
2014-05-13 |
2022-11-22 |
Chugai Seiyaku Kabushiki Kaisha |
T cell-redirected antigen-binding molecule for cells having immunosuppression function
|
WO2016001810A1
(en)
|
2014-07-01 |
2016-01-07 |
Pfizer Inc. |
Bispecific heterodimeric diabodies and uses thereof
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
CN106687483B
(zh)
|
2014-07-21 |
2020-12-04 |
诺华股份有限公司 |
使用人源化抗-bcma嵌合抗原受体治疗癌症
|
EP3193915A1
(de)
|
2014-07-21 |
2017-07-26 |
Novartis AG |
Kombinationen aus niedrigen, immunfördernden dosen von mtor-inhibitoren und cars
|
CN107109419B
(zh)
|
2014-07-21 |
2020-12-22 |
诺华股份有限公司 |
使用cd33嵌合抗原受体治疗癌症
|
TW201609812A
(zh)
|
2014-07-31 |
2016-03-16 |
安美基研究(慕尼黑)公司 |
最佳化之跨物種特異性雙特異性單鏈抗體構築體
|
US20170209492A1
(en)
|
2014-07-31 |
2017-07-27 |
Novartis Ag |
Subset-optimized chimeric antigen receptor-containing t-cells
|
WO2016025880A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using gfr alpha-4 chimeric antigen receptor
|
JP7084138B2
(ja)
|
2014-08-19 |
2022-06-14 |
ノバルティス アーゲー |
癌処置に使用するための抗cd123キメラ抗原受容体(car)
|
TWI711629B
(zh)
*
|
2014-09-03 |
2020-12-01 |
德商包林格因蓋爾漢國際股份有限公司 |
靶向IL-23A與TNF-α之化合物及其用途
|
KR20230149327A
(ko)
|
2014-09-17 |
2023-10-26 |
노파르티스 아게 |
입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
|
SG11201702401RA
(en)
|
2014-10-14 |
2017-04-27 |
Novartis Ag |
Antibody molecules to pd-l1 and uses thereof
|
CN104403004B
(zh)
*
|
2014-11-24 |
2017-10-13 |
苏州丁孚靶点生物技术有限公司 |
抗体‑干扰素异二聚体的制备和用途
|
WO2016090034A2
(en)
|
2014-12-03 |
2016-06-09 |
Novartis Ag |
Methods for b cell preconditioning in car therapy
|
CN107427590B
(zh)
|
2015-02-02 |
2021-08-31 |
伯明翰大学 |
具有多个t细胞表位的靶向部分肽表位复合物
|
BR112017021500A2
(pt)
|
2015-04-08 |
2018-09-25 |
Novartis Ag |
terapias com cd20, terapias com cd22 e terapias de combinação com uma célula que expressa (car) receptor de antígeno quimérico de cd19
|
WO2016166139A1
(en)
*
|
2015-04-14 |
2016-10-20 |
Eberhard Karls Universität Tübingen |
Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
|
TW202311292A
(zh)
|
2015-04-17 |
2023-03-16 |
德商安美基研究(慕尼黑)公司 |
Cdh3與cd3之雙特異性抗體構築體
|
EP3286211A1
(de)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Behandlung von krebs mit chimärem antigenrezeptor- und proteinkinase-a-blocker
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
EP3964528A1
(de)
|
2015-07-29 |
2022-03-09 |
Novartis AG |
Kombinationstherapien mit antikörpermolekülen gegen lag-3
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
TW202346349A
(zh)
|
2015-07-31 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
JO3620B1
(ar)
|
2015-08-05 |
2020-08-27 |
Amgen Res Munich Gmbh |
مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
|
UA126278C2
(uk)
|
2015-09-21 |
2022-09-14 |
Аптево Рісьорч Енд Девелопмент Ллс |
Поліпептиди, які зв'язують cd3
|
WO2017086367A1
(ja)
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法
|
JP6925278B2
(ja)
*
|
2015-11-18 |
2021-08-25 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
EP3377103B1
(de)
|
2015-11-19 |
2021-03-17 |
Revitope Limited |
Komplementierung eines funktionellen antikörperfragments für ein zwei-komponenten-system zur umgelenkten tötung unerwünschter zellen
|
CN108697794A
(zh)
|
2015-12-17 |
2018-10-23 |
诺华股份有限公司 |
C-met抑制剂和抗pd-1抗体分子的组合及其用途
|
CN108495651A
(zh)
|
2015-12-17 |
2018-09-04 |
诺华股份有限公司 |
抗pd-1的抗体分子及其用途
|
WO2017125897A1
(en)
|
2016-01-21 |
2017-07-27 |
Novartis Ag |
Multispecific molecules targeting cll-1
|
DK3411402T3
(da)
|
2016-02-03 |
2022-02-07 |
Amgen Res Munich Gmbh |
Bcma- og cd3-bispecifikke t-celle-engagerende antistofkonstruktioner
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
EP3411404B1
(de)
|
2016-02-03 |
2022-11-09 |
Amgen Research (Munich) GmbH |
Psma- und cd3-bispezifische t-zellaktivierende antikörperkonstrukte
|
BR112018067679A2
(pt)
|
2016-03-04 |
2019-01-15 |
Novartis Ag |
células que expressam múltiplas moléculas do receptor de antígeno quimérico (car) e seu uso
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
CN109715808A
(zh)
|
2016-04-15 |
2019-05-03 |
诺华股份有限公司 |
用于选择性蛋白质表达的组合物和方法
|
JOP20170091B1
(ar)
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
|
WO2017210617A2
(en)
|
2016-06-02 |
2017-12-07 |
Porter, David, L. |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
CN110461315A
(zh)
|
2016-07-15 |
2019-11-15 |
诺华股份有限公司 |
使用与激酶抑制剂组合的嵌合抗原受体治疗和预防细胞因子释放综合征
|
AU2017302668B9
(en)
|
2016-07-28 |
2023-06-22 |
Novartis Ag |
Combination therapies of chimeric antigen receptors and PD-1 inhibitors
|
CA3032581A1
(en)
|
2016-08-01 |
2018-02-08 |
Novartis Ag |
Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
|
EP3523331A1
(de)
|
2016-10-07 |
2019-08-14 |
Novartis AG |
Chimäre antigenrezeptoren zur behandlung von krebs
|
WO2018140725A1
(en)
|
2017-01-26 |
2018-08-02 |
Novartis Ag |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
EP3589647A1
(de)
|
2017-02-28 |
2020-01-08 |
Novartis AG |
Shp-inhibitor-zusammensetzungen und verwendungen zur chimären antigenrezeptortherapie
|
US10961310B2
(en)
|
2017-03-15 |
2021-03-30 |
Pandion Operations, Inc. |
Targeted immunotolerance
|
US20200055948A1
(en)
|
2017-04-28 |
2020-02-20 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
WO2018201051A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
KR20190141243A
(ko)
|
2017-05-05 |
2019-12-23 |
암젠 인크 |
개선된 저장 및 투여를 위한 이중특이적 항체 구축물을 포함하는 약제학적 조성물
|
BR112019024127A2
(pt)
|
2017-05-24 |
2020-06-23 |
Pandion Therapeutics, Inc. |
Imunotolerância alvejada
|
WO2018226985A2
(en)
*
|
2017-06-07 |
2018-12-13 |
Antibody Biopharm, Inc. |
Guided combinational therapeutic antibody
|
AR112257A1
(es)
|
2017-06-21 |
2019-10-09 |
Gilead Sciences Inc |
Anticuerpos multiespecíficos dirigidos al vih-1 gp120 y cd3 humana, composiciones que los comprende, ácido nucleico, vector y célula huésped relacionados, método para producirlos, método para detectar células que expresan gp120 y cd3, kit de anticuerpos, fragmentos de anticuerpo que se une a gp120 y método para producirlos
|
CR20190593A
(es)
|
2017-06-22 |
2020-05-10 |
Novartis Ag |
Moléculas de anticuerpo que se unen a cd73 y usos de las mismas
|
KR20200022447A
(ko)
|
2017-06-27 |
2020-03-03 |
노파르티스 아게 |
항-tim-3 항체의 투여 요법 및 그의 용도
|
AU2018302283A1
(en)
|
2017-07-20 |
2020-02-06 |
Novartis Ag |
Dosage regimens of anti-LAG-3 antibodies and uses thereof
|
US20210179709A1
(en)
|
2017-10-31 |
2021-06-17 |
Novartis Ag |
Anti-car compositions and methods
|
GB201718088D0
(en)
*
|
2017-11-01 |
2017-12-13 |
Autolus Ltd |
Vectors
|
JP2021503478A
(ja)
|
2017-11-16 |
2021-02-12 |
ノバルティス アーゲー |
組み合わせ治療
|
US10174092B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
EP3724229A1
(de)
|
2017-12-11 |
2020-10-21 |
Amgen Inc. |
Kontinuierliches herstellungsverfahren für bispezifische antikörperprodukte
|
TW201940518A
(zh)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
針對muc17和cd3之雙特異性抗體構建體
|
WO2019152660A1
(en)
|
2018-01-31 |
2019-08-08 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
CN112384534A
(zh)
|
2018-05-21 |
2021-02-19 |
指南针制药有限责任公司 |
用于增强nk细胞对靶细胞的杀死的组合物和方法
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
WO2019227003A1
(en)
|
2018-05-25 |
2019-11-28 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
BR112020025048A2
(pt)
|
2018-06-13 |
2021-04-06 |
Novartis Ag |
Receptores de antígeno quimérico de bcma e usos dos mesmos
|
JP7472119B2
(ja)
|
2018-06-19 |
2024-04-22 |
アターガ,エルエルシー |
補体第5成分に対する抗体分子およびその使用
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
TW202021616A
(zh)
|
2018-07-30 |
2020-06-16 |
美商安進公司 |
結合至cd33和cd3的雙特異性抗體構建體之延長投與
|
EP3830122A1
(de)
|
2018-07-31 |
2021-06-09 |
Amgen Research (Munich) GmbH |
Dosierungsschema für bispezifische bcma-cd3-antikörper
|
AR114541A1
(es)
|
2018-08-03 |
2020-09-16 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cldn18.2 y cd3
|
MA53732A
(fr)
|
2018-09-28 |
2022-01-05 |
Amgen Inc |
Anticorps dirigés contre bcma soluble
|
EP3862366A4
(de)
*
|
2018-10-05 |
2022-06-29 |
Sapporo Medical University |
Für krebsstammzellen spezifischer antikörper
|
AU2019356564A1
(en)
|
2018-10-11 |
2021-04-29 |
Amgen Inc. |
Downstream processing of bispecific antibody constructs
|
WO2020128972A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
WO2020128894A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer
|
CA3124935A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
WO2020165834A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
US20220088075A1
(en)
|
2019-02-22 |
2022-03-24 |
The Trustees Of The University Of Pennsylvania |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
EP3946593A1
(de)
|
2019-03-29 |
2022-02-09 |
Atarga, LLC |
Antikörper gegen fgf23
|
CN114679909A
(zh)
|
2019-05-20 |
2022-06-28 |
潘迪恩运营公司 |
MAdCAM靶向的免疫耐受
|
AU2020290573A1
(en)
|
2019-06-13 |
2021-11-04 |
Amgen Inc. |
Automated biomass-based perfusion control in the manufacturing of biologics
|
AU2020345787A1
(en)
|
2019-09-10 |
2022-03-24 |
Amgen Inc. |
Purification method for bispecific antigen-binding polypeptides with enhanced protein L capture dynamic binding capacity
|
WO2021079188A1
(en)
|
2019-10-21 |
2021-04-29 |
Novartis Ag |
Combination therapies with venetoclax and tim-3 inhibitors
|
BR112022007179A2
(pt)
|
2019-10-21 |
2022-08-23 |
Novartis Ag |
Inibidores de tim-3 e usos dos mesmos
|
EP3819007A1
(de)
|
2019-11-11 |
2021-05-12 |
Amgen Research (Munich) GmbH |
Dosierschema für anti-bcma-wirkstoffe
|
US20220396599A1
(en)
|
2019-11-13 |
2022-12-15 |
Amgen Inc. |
Method for Reduced Aggregate Formation in Downstream Processing of Bispecific Antigen-Binding Molecules
|
KR20220105664A
(ko)
|
2019-11-26 |
2022-07-27 |
노파르티스 아게 |
Bcma 및 cd19에 결합하는 키메라 항원 수용체 및 이의 용도
|
US20230056470A1
(en)
|
2019-12-20 |
2023-02-23 |
Novartis Ag |
Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
|
CA3164129A1
(en)
|
2019-12-20 |
2021-06-24 |
Amgen Inc. |
Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors
|
CN115298322A
(zh)
|
2020-01-17 |
2022-11-04 |
贝克顿迪金森公司 |
用于单细胞分泌组学的方法和组合物
|
US20230058489A1
(en)
|
2020-01-17 |
2023-02-23 |
Novartis Ag |
Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
EP4093771A1
(de)
|
2020-01-22 |
2022-11-30 |
Amgen Research (Munich) GmbH |
Kombinationen von antikörperkonstrukten und inhibitoren des zytokinfreisetzungssyndroms und verwendungen davon
|
MX2022010685A
(es)
|
2020-02-27 |
2022-09-23 |
Novartis Ag |
Metodos de produccion de celulas que expresan receptores de antigeno quimericos.
|
WO2021183861A1
(en)
|
2020-03-12 |
2021-09-16 |
Amgen Inc. |
Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
|
WO2021188851A1
(en)
|
2020-03-19 |
2021-09-23 |
Amgen Inc. |
Antibodies against mucin 17 and uses thereof
|
AU2021275049A1
(en)
|
2020-05-19 |
2022-12-22 |
Amgen Inc. |
MAGEB2 binding constructs
|
TW202210101A
(zh)
|
2020-05-29 |
2022-03-16 |
美商安進公司 |
與cd33和cd3結合的雙特異性構建體的減輕不良反應投與
|
BR112023000482A2
(pt)
|
2020-07-16 |
2023-01-31 |
Novartis Ag |
Anticorpos antibetacelulina, fragmentos dos mesmos e moléculas de ligação multiespecíficas
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
CN116134027A
(zh)
|
2020-08-03 |
2023-05-16 |
诺华股份有限公司 |
杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
WO2022043557A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
WO2022043558A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
JP2023547499A
(ja)
|
2020-11-06 |
2023-11-10 |
ノバルティス アーゲー |
抗体Fc変異体
|
KR20230104256A
(ko)
|
2020-11-06 |
2023-07-07 |
암젠 인크 |
증가된 선택성의 다중표적화 이중특이적 항원 결합 분자
|
TW202233678A
(zh)
|
2020-11-06 |
2022-09-01 |
德商安美基研究(慕尼黑)公司 |
具有增強的剪切特徵的多肽
|
CA3199931A1
(en)
|
2020-11-06 |
2022-05-12 |
Amgen Inc. |
Polypeptide constructs binding to cd3
|
AU2021374036A1
(en)
|
2020-11-06 |
2023-06-08 |
Amgen Inc. |
Polypeptide constructs selectively binding to cldn6 and cd3
|
WO2022103781A1
(en)
|
2020-11-10 |
2022-05-19 |
Amgen Inc. |
Methods for administering a bcma x cd3 binding molecule
|
CN116635062A
(zh)
|
2020-11-13 |
2023-08-22 |
诺华股份有限公司 |
使用表达嵌合抗原受体(car)的细胞的组合疗法
|
JP2024505049A
(ja)
|
2021-01-29 |
2024-02-02 |
ノバルティス アーゲー |
抗cd73及び抗entpd2抗体のための投与方式並びにその使用
|
CA3215594A1
(en)
|
2021-04-02 |
2022-10-06 |
Agnieszka KIELCZEWSKA |
Mageb2 binding constructs
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
AU2022269312A1
(en)
|
2021-05-06 |
2023-10-19 |
Amgen Research (Munich) Gmbh |
Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
|
CA3233696A1
(en)
|
2021-11-03 |
2023-05-11 |
Joachim Koch |
Bispecific cd16a binders
|
CA3237018A1
(en)
|
2021-11-03 |
2023-05-11 |
Joachim Koch |
Bispecific cd16a binders
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
US20230383010A1
(en)
|
2022-02-07 |
2023-11-30 |
Visterra, Inc. |
Anti-idiotype antibody molecules and uses thereof
|
TW202400658A
(zh)
|
2022-04-26 |
2024-01-01 |
瑞士商諾華公司 |
靶向il—13和il—18的多特異性抗體
|
WO2023218027A1
(en)
|
2022-05-12 |
2023-11-16 |
Amgen Research (Munich) Gmbh |
Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
WO2024030976A2
(en)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|